Daewoong Pharma
KRX:069620
Daewoong Pharma
KRX:069620
Price:
140 000
KRW
3.32%
Market Closed
Market Cap:
1.6T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Daewoong Pharma
140000
+4500 (+3.32%)
| 52 Week Range |
99 900
150 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Daewoong Pharma
Income Statement
Earnings Waterfall
Daewoong Pharma
Daewoong Pharma
|
Revenue
|
1.4T
KRW
|
|
Cost of Revenue
|
-690.8B
KRW
|
|
Gross Profit
|
708.3B
KRW
|
|
Operating Expenses
|
-578.3B
KRW
|
|
Operating Income
|
130B
KRW
|
|
Other Expenses
|
-39.2B
KRW
|
|
Net Income
|
90.9B
KRW
|
Income Statement
Daewoong Pharma
Daewoong Pharma
Currency: KRW
| Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Revenue |
714 185
N/A
|
734 716
+3%
|
735 889
+0%
|
758 475
+3%
|
778 975
+3%
|
812 337
+4%
|
839 686
+3%
|
857 252
+2%
|
869 025
+1%
|
862 689
-1%
|
883 920
+2%
|
898 632
+2%
|
927 951
+3%
|
959 672
+3%
|
960 307
+0%
|
973 799
+1%
|
990 152
+2%
|
995 896
+1%
|
1 031 427
+4%
|
1 055 676
+2%
|
1 086 724
+3%
|
1 098 179
+1%
|
1 113 426
+1%
|
1 107 157
-1%
|
1 068 432
-3%
|
1 075 830
+1%
|
1 055 424
-2%
|
1 067 635
+1%
|
1 103 386
+3%
|
1 117 201
+1%
|
1 152 976
+3%
|
1 181 714
+2%
|
1 214 081
+3%
|
1 255 325
+3%
|
1 280 092
+2%
|
1 304 151
+2%
|
1 332 284
+2%
|
1 341 290
+1%
|
1 375 329
+3%
|
1 388 699
+1%
|
1 399 052
+1%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(434 614)
|
(461 788)
|
(465 702)
|
(485 379)
|
(505 166)
|
(534 268)
|
(537 083)
|
(534 868)
|
(522 535)
|
(498 684)
|
(510 232)
|
(520 519)
|
(541 486)
|
(557 283)
|
(553 325)
|
(563 015)
|
(578 937)
|
(592 845)
|
(621 485)
|
(631 009)
|
(635 624)
|
(628 430)
|
(635 132)
|
(627 798)
|
(612 242)
|
(629 522)
|
(608 482)
|
(604 487)
|
(610 706)
|
(599 663)
|
(608 403)
|
(622 105)
|
(627 969)
|
(635 304)
|
(641 134)
|
(649 782)
|
(657 910)
|
(670 624)
|
(687 162)
|
(688 506)
|
(690 765)
|
|
| Gross Profit |
279 572
N/A
|
272 929
-2%
|
270 187
-1%
|
273 097
+1%
|
273 809
+0%
|
278 070
+2%
|
302 603
+9%
|
322 384
+7%
|
346 490
+7%
|
364 003
+5%
|
373 688
+3%
|
378 112
+1%
|
386 464
+2%
|
402 389
+4%
|
406 982
+1%
|
410 785
+1%
|
411 216
+0%
|
403 052
-2%
|
409 943
+2%
|
424 667
+4%
|
451 101
+6%
|
469 751
+4%
|
478 293
+2%
|
479 362
+0%
|
456 192
-5%
|
446 310
-2%
|
446 942
+0%
|
463 149
+4%
|
492 682
+6%
|
517 539
+5%
|
544 573
+5%
|
559 610
+3%
|
586 112
+5%
|
620 021
+6%
|
638 958
+3%
|
654 369
+2%
|
674 373
+3%
|
670 666
-1%
|
688 167
+3%
|
700 194
+2%
|
708 287
+1%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(213 994)
|
(217 029)
|
(218 243)
|
(223 614)
|
(225 605)
|
(233 939)
|
(259 039)
|
(287 553)
|
(322 275)
|
(345 896)
|
(347 794)
|
(350 722)
|
(354 844)
|
(360 668)
|
(368 026)
|
(374 753)
|
(375 314)
|
(373 512)
|
(385 377)
|
(407 935)
|
(419 128)
|
(438 767)
|
(433 606)
|
(441 735)
|
(444 539)
|
(434 948)
|
(429 962)
|
(429 180)
|
(436 785)
|
(444 849)
|
(455 844)
|
(470 216)
|
(485 388)
|
(511 911)
|
(543 160)
|
(557 146)
|
(567 127)
|
(564 137)
|
(565 575)
|
(572 415)
|
(578 251)
|
|
| Selling, General & Administrative |
(188 523)
|
(191 618)
|
(194 727)
|
(199 620)
|
(204 018)
|
(209 625)
|
(220 747)
|
(227 859)
|
(240 400)
|
(245 353)
|
(234 982)
|
(238 438)
|
(237 733)
|
(240 667)
|
(251 511)
|
(250 435)
|
(253 814)
|
(253 574)
|
(262 206)
|
(272 495)
|
(285 442)
|
(306 704)
|
(316 079)
|
(326 737)
|
(325 823)
|
(312 194)
|
(307 437)
|
(298 932)
|
(303 584)
|
(311 740)
|
(321 936)
|
(331 141)
|
(341 162)
|
(358 085)
|
(373 502)
|
(380 420)
|
(387 975)
|
(383 984)
|
(387 385)
|
(396 864)
|
(399 549)
|
|
| Research & Development |
(20 873)
|
(20 823)
|
(18 743)
|
(17 819)
|
(15 270)
|
(17 128)
|
(31 068)
|
(51 711)
|
(73 045)
|
(91 898)
|
(103 691)
|
(103 120)
|
(106 849)
|
(111 735)
|
(107 939)
|
(113 572)
|
(112 330)
|
(109 109)
|
(113 812)
|
(110 988)
|
(111 093)
|
(110 485)
|
(109 441)
|
(107 536)
|
(111 557)
|
(115 678)
|
(115 218)
|
(122 936)
|
(125 982)
|
(126 287)
|
(127 269)
|
(132 725)
|
(137 991)
|
(147 550)
|
(163 602)
|
(170 379)
|
(172 737)
|
(173 689)
|
(171 573)
|
(168 094)
|
(170 305)
|
|
| Depreciation & Amortization |
(4 599)
|
(4 589)
|
(4 774)
|
(5 090)
|
(5 231)
|
(6 369)
|
(7 224)
|
(7 982)
|
(8 828)
|
(8 643)
|
(9 121)
|
(9 164)
|
(9 026)
|
(8 268)
|
(8 576)
|
(8 353)
|
(9 170)
|
(10 830)
|
(9 359)
|
(9 345)
|
(8 550)
|
(7 533)
|
(8 087)
|
(7 464)
|
(7 160)
|
(7 077)
|
(7 307)
|
(7 312)
|
(7 219)
|
(6 822)
|
(6 638)
|
(6 350)
|
(6 236)
|
(6 276)
|
(6 057)
|
(6 348)
|
(6 415)
|
(6 465)
|
(6 616)
|
(7 457)
|
(8 397)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
(1 085)
|
(1 086)
|
(817)
|
0
|
0
|
0
|
0
|
0
|
0
|
(1 236)
|
0
|
0
|
(2 393)
|
0
|
0
|
0
|
(15 107)
|
(14 043)
|
(14 045)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
65 578
N/A
|
55 900
-15%
|
51 944
-7%
|
49 483
-5%
|
48 205
-3%
|
44 132
-8%
|
43 564
-1%
|
34 832
-20%
|
24 216
-30%
|
18 109
-25%
|
25 894
+43%
|
27 390
+6%
|
31 620
+15%
|
41 720
+32%
|
38 957
-7%
|
36 031
-8%
|
35 901
0%
|
29 538
-18%
|
24 566
-17%
|
16 730
-32%
|
31 971
+91%
|
30 983
-3%
|
44 688
+44%
|
37 626
-16%
|
11 652
-69%
|
11 360
-3%
|
16 980
+49%
|
33 968
+100%
|
55 896
+65%
|
72 689
+30%
|
88 729
+22%
|
89 394
+1%
|
100 724
+13%
|
108 110
+7%
|
95 797
-11%
|
97 222
+1%
|
107 246
+10%
|
106 528
-1%
|
122 592
+15%
|
127 779
+4%
|
130 037
+2%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
173
|
78
|
2 028
|
2 417
|
1 998
|
1 653
|
896
|
(206)
|
(609)
|
(2 417)
|
(1 771)
|
(4 219)
|
(4 733)
|
(4 121)
|
(9 542)
|
(8 401)
|
(6 809)
|
(8 469)
|
(6 475)
|
(5 321)
|
(6 724)
|
(4 058)
|
(5 226)
|
(5 064)
|
(993)
|
(1 749)
|
8 124
|
10 372
|
5 006
|
4 377
|
7 923
|
(1 799)
|
(4 639)
|
(168)
|
(4 694)
|
(5 199)
|
(2 172)
|
(9 650)
|
(17 239)
|
(20 103)
|
(12 614)
|
|
| Non-Reccuring Items |
0
|
(269)
|
(1 084)
|
0
|
0
|
0
|
(17)
|
(24)
|
(37)
|
(170)
|
(1 245)
|
(1 251)
|
0
|
(1 178)
|
(2 406)
|
0
|
(3 457)
|
(3 383)
|
(15 107)
|
0
|
0
|
0
|
(9 317)
|
0
|
0
|
0
|
(8 988)
|
0
|
0
|
0
|
(2 310)
|
0
|
0
|
0
|
(5 219)
|
0
|
0
|
0
|
29 464
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
158
|
(43)
|
(75)
|
(80)
|
(242)
|
(168)
|
(764)
|
(813)
|
(699)
|
(497)
|
(81)
|
(35)
|
(138)
|
72
|
271
|
280
|
(890)
|
(1 170)
|
(9 238)
|
0
|
0
|
0
|
(17)
|
0
|
0
|
0
|
(720)
|
0
|
0
|
0
|
(1 029)
|
0
|
0
|
0
|
246
|
0
|
0
|
0
|
(1 221)
|
0
|
0
|
|
| Total Other Income |
4 472
|
968
|
873
|
1 170
|
1 098
|
4 711
|
4 072
|
3 777
|
4 590
|
5 359
|
4 813
|
4 464
|
8 689
|
8 051
|
8 853
|
9 759
|
5 882
|
6 429
|
5 632
|
(6 107)
|
(14 556)
|
(16 231)
|
(6 806)
|
(15 781)
|
(15 057)
|
(15 405)
|
(1 837)
|
(62 701)
|
(57 712)
|
(60 878)
|
(73 553)
|
(19 631)
|
(18 532)
|
(19 591)
|
(47 801)
|
(52 788)
|
(55 194)
|
(53 865)
|
(11 596)
|
4 240
|
(12 423)
|
|
| Pre-Tax Income |
70 381
N/A
|
56 633
-20%
|
53 685
-5%
|
52 990
-1%
|
51 058
-4%
|
50 327
-1%
|
47 751
-5%
|
37 565
-21%
|
27 460
-27%
|
20 384
-26%
|
27 609
+35%
|
26 348
-5%
|
35 438
+34%
|
44 543
+26%
|
36 133
-19%
|
37 670
+4%
|
30 627
-19%
|
22 946
-25%
|
(623)
N/A
|
5 302
N/A
|
10 691
+102%
|
10 694
+0%
|
23 322
+118%
|
16 781
-28%
|
(4 398)
N/A
|
(5 794)
-32%
|
13 559
N/A
|
(18 361)
N/A
|
3 191
N/A
|
16 189
+407%
|
19 761
+22%
|
67 963
+244%
|
77 553
+14%
|
88 351
+14%
|
38 330
-57%
|
39 235
+2%
|
49 880
+27%
|
43 013
-14%
|
121 999
+184%
|
111 916
-8%
|
105 000
-6%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
(14 383)
|
(26 455)
|
(23 215)
|
(23 376)
|
(23 405)
|
(9 130)
|
(12 078)
|
(9 792)
|
(7 372)
|
(5 038)
|
(1 483)
|
(1 521)
|
(4 465)
|
(5 871)
|
(696)
|
(1 164)
|
1 440
|
3 146
|
(14 795)
|
(15 987)
|
(17 145)
|
(16 300)
|
5 544
|
7 432
|
14 227
|
13 523
|
10 589
|
18 625
|
9 564
|
5 223
|
10 323
|
(3 742)
|
(6 055)
|
(7 620)
|
834
|
611
|
2 482
|
3 399
|
(1 996)
|
2 224
|
(20 934)
|
|
| Income from Continuing Operations |
55 999
|
30 179
|
30 470
|
29 613
|
27 651
|
41 196
|
35 674
|
27 773
|
20 089
|
15 346
|
26 126
|
24 827
|
30 973
|
38 672
|
35 436
|
36 507
|
32 068
|
26 094
|
(15 417)
|
(10 685)
|
(6 454)
|
(5 607)
|
28 866
|
24 214
|
9 829
|
7 728
|
24 148
|
261
|
12 753
|
21 412
|
30 084
|
64 221
|
71 498
|
80 731
|
39 163
|
39 846
|
52 362
|
46 412
|
120 003
|
114 141
|
84 066
|
|
| Income to Minority Interest |
701
|
997
|
1 075
|
942
|
925
|
3 462
|
7 256
|
6 640
|
5 932
|
4 357
|
844
|
2 605
|
3 480
|
645
|
(3 856)
|
(5 430)
|
(6 773)
|
(6 484)
|
265
|
(1 395)
|
140
|
(2 414)
|
(6 860)
|
(7 385)
|
(12 309)
|
(9 385)
|
(11 395)
|
(11 291)
|
(9 782)
|
(9 873)
|
(5 578)
|
(2 835)
|
1 233
|
1 532
|
3 076
|
4 184
|
(1 058)
|
(31)
|
1 736
|
334
|
6 807
|
|
| Net Income (Common) |
56 701
N/A
|
31 177
-45%
|
31 544
+1%
|
30 556
-3%
|
28 577
-6%
|
44 658
+56%
|
42 930
-4%
|
34 414
-20%
|
26 022
-24%
|
19 705
-24%
|
26 970
+37%
|
27 433
+2%
|
34 454
+26%
|
39 318
+14%
|
31 581
-20%
|
31 077
-2%
|
25 296
-19%
|
19 610
-22%
|
(15 152)
N/A
|
(12 078)
+20%
|
(6 313)
+48%
|
(8 020)
-27%
|
22 006
N/A
|
16 828
-24%
|
(2 481)
N/A
|
(1 658)
+33%
|
12 753
N/A
|
(11 030)
N/A
|
2 971
N/A
|
11 539
+288%
|
24 506
+112%
|
61 386
+150%
|
72 731
+18%
|
82 263
+13%
|
42 240
-49%
|
44 030
+4%
|
51 305
+17%
|
46 381
-10%
|
121 739
+162%
|
114 474
-6%
|
90 872
-21%
|
|
| EPS (Diluted) |
5 670.1
N/A
|
3 117.7
-45%
|
3 154.4
+1%
|
3 055.6
-3%
|
2 857.7
-6%
|
4 465.8
+56%
|
4 293
-4%
|
3 441.4
-20%
|
2 602.19
-24%
|
1 970.5
-24%
|
2 697
+37%
|
2 743.3
+2%
|
3 445.4
+26%
|
3 931.8
+14%
|
3 158.1
-20%
|
3 107.7
-2%
|
2 529.6
-19%
|
1 961
-22%
|
-1 515.2
N/A
|
-1 207.8
+20%
|
-631.29
+48%
|
-802
-27%
|
2 200.6
N/A
|
1 682.8
-24%
|
-225.54
N/A
|
-150.72
+33%
|
1 159.36
N/A
|
-1 002.72
N/A
|
268.38
N/A
|
1 042.4
+288%
|
2 226.87
+114%
|
5 544.22
+149%
|
6 570.6
+19%
|
7 431.67
+13%
|
3 815.95
-49%
|
3 939.68
+3%
|
4 458.83
+13%
|
4 030.93
-10%
|
10 656.06
+164%
|
9 948.85
-7%
|
7 897.63
-21%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
